ARTICLE | Financial News
Repare launches with $68M
June 22, 2017 11:45 AM UTC
Repare Therapeutics Inc. (Montreal, Quebec) launched with a $68 million series A round. Versant Ventures, which founded the company, co-led the round with MPM Capital. Also participating were Fonds de solidarité FTQ, the Celgene Switzerland LLC affiliate of Celgene Corp. (NASDAQ:CELG) and BDC Capital’s Healthcare Venture Fund.
The newco is using a CRISPR-based platform to identify novel targets that have synthetic lethal interactions with specific cancer-associated genomic defects. Synthetic lethality is a phenomenon in which genomic or pharmacologically induced defects that are tolerated individually become lethal when combined...
BCIQ Target Profiles